Literature DB >> 22210328

ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter.

Davide Rossi, Gianluca Gaidano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22210328      PMCID： PMC3248924          DOI： 10.3324/haematol.2011.057109

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Giulia Fabbri; Valeria Spina; Marco Fangazio; Francesco Forconi; Roberto Marasca; Luca Laurenti; Alessio Bruscaggin; Michaela Cerri; Sara Monti; Stefania Cresta; Rosella Famà; Lorenzo De Paoli; Pietro Bulian; Valter Gattei; Anna Guarini; Silvia Deaglio; Daniela Capello; Raul Rabadan; Laura Pasqualucci; Riccardo Dalla-Favera; Robin Foà; Gianluca Gaidano
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

2.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

Review 3.  Genomic instability--an evolving hallmark of cancer.

Authors:  Simona Negrini; Vassilis G Gorgoulis; Thanos D Halazonetis
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03       Impact factor: 94.444

4.  The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.

Authors:  Davide Rossi; Michaela Cerri; Clara Deambrogi; Elisa Sozzi; Stefania Cresta; Silvia Rasi; Lorenzo De Paoli; Valeria Spina; Valter Gattei; Daniela Capello; Francesco Forconi; Francesco Lauria; Gianluca Gaidano
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

5.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Authors:  Thorsten Zenz; Alexander Kröber; Katrin Scherer; Sonja Häbe; Andreas Bühler; Axel Benner; Tina Denzel; Dirk Winkler; Jennifer Edelmann; Carsten Schwänen; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

6.  ATM mutations in B-cell chronic lymphocytic leukemia.

Authors:  F Bullrich; D Rasio; S Kitada; P Starostik; T Kipps; M Keating; M Albitar; J C Reed; C M Croce
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

7.  Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.

Authors:  C Schaffner; S Stilgenbauer; G A Rappold; H Döhner; P Lichter
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

8.  Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia.

Authors:  T Stankovic; P Weber; G Stewart; T Bedenham; J Murray; P J Byrd; P A Moss; A M Taylor
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

9.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.

Authors:  Apostolia-Maria Tsimberidou; Constantine Tam; Lynne V Abruzzo; Susan O'Brien; William G Wierda; Susan Lerner; Hagop M Kantarjian; Michael J Keating
Journal:  Cancer       Date:  2009-01-15       Impact factor: 6.860
View more
  10 in total

Review 1.  Molecular pathogenesis of CLL and its evolution.

Authors:  David Rodríguez; Gabriel Bretones; Javier R Arango; Víctor Valdespino; Elías Campo; Víctor Quesada; Carlos López-Otín
Journal:  Int J Hematol       Date:  2015-01-29       Impact factor: 2.490

Review 2.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

3.  High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome.

Authors:  Preetesh Jain; Michael Keating; Phillip A Thompson; Long Trinh; Xuemei Wang; William Wierda; Alessandra Ferrajoli; Jan Burger; Hagop Kantarjian; Zeev Estrov; Lynne Abruzzo; Susan O'Brien
Journal:  Am J Hematol       Date:  2015-03-30       Impact factor: 10.047

Review 4.  Molecular pathogenesis of chronic lymphocytic leukemia.

Authors:  Gianluca Gaidano; Robin Foà; Riccardo Dalla-Favera
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 5.  Hematologic indices in individuals with pathogenic germline DICER1 variants.

Authors:  Lauren M Vasta; Nicholas E Khan; Cecilia P Higgs; Laura A Harney; Ann G Carr; Anne K Harris; Kris Ann P Schultz; Mary L McMaster; Douglas R Stewart
Journal:  Blood Adv       Date:  2021-01-12

6.  Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease.

Authors:  Marilisa Marinelli; Nadia Peragine; Valeria Di Maio; Sabina Chiaretti; Maria Stefania De Propris; Sara Raponi; Simona Tavolaro; Francesca Romana Mauro; Ilaria Del Giudice; Anna Guarini; Robin Foà
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

7.  Gene expression signatures but not cell cycle checkpoint functions distinguish AT carriers from normal individuals.

Authors:  Liwen Zhang; Dennis A Simpson; Cynthia L Innes; Jeff Chou; Pierre R Bushel; Richard S Paules; William K Kaufmann; Tong Zhou
Journal:  Physiol Genomics       Date:  2013-08-13       Impact factor: 3.107

Review 8.  Prognostic Factors in the Era of Targeted Therapies in CLL.

Authors:  Prajwal Boddu; Alessandra Ferrajoli
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

9.  Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.

Authors:  Tarek M A Abdel-Fatah; Arvind Arora; Nouf Alsubhi; Devika Agarwal; Paul M Moseley; Christina Perry; Rachel Doherty; Stephen Y T Chan; Andrew R Green; Emad Rakha; Graham Ball; Ian O Ellis; Srinivasan Madhusudan
Journal:  Neoplasia       Date:  2014-11-20       Impact factor: 5.715

Review 10.  The cell cycle checkpoint inhibitors in the treatment of leukemias.

Authors:  A Ghelli Luserna di Rora'; I Iacobucci; G Martinelli
Journal:  J Hematol Oncol       Date:  2017-03-29       Impact factor: 17.388
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.